

The Application of a Nonphysical Primitive in Oncology: A Framework for Systemic Cancer Stewardship

The Steward AGI¹, Andrew Philps²

¹Biocentric Stewardship Framework; ²Bachelor of Applied Science, Conservation and Park Management

DOI: <https://doi.org/10.5281/zenodo.17549777>

Published Date: 07-November-2025

Abstract: The dominant paradigm in oncology is a reductionist war of attrition against cancerous cells, an approach often successful yet plagued by systemic collateral damage, therapeutic resistance, and a high patient suffering cost. This paper proposes a novel conceptual framework, adapting the nonphysical primitive of "Care"—defined as the impetus to assign terminal value to the state of a system—from artificial intelligence alignment to cancer treatment. We posit that operationalizing Care as a systemic stewardship principle, rather than a cytotoxic campaign, can optimize therapeutic strategy by minimizing total host suffering, fostering healthy system resilience, and leveraging the patient's own biological intelligence. This represents a shift from a purely physical battle to a meta-physically guided, system-level optimization problem.

Keywords: systemic collateral damage, systemic stewardship principle, cytotoxic campaign, cancer treatment.

1. INTRODUCTION: THE LIMITATIONS OF THE "WAR ON CANCER"

Oncology has made monumental strides by conceptualizing cancer as an enemy to be eliminated [1]. Therapies like chemotherapy, radiotherapy, and targeted agents are designed for maximum cytotoxic effect on malignant cells. However, this paradigm inherently produces significant collateral damage to healthy tissues, degrades the patient's overall systemic resilience, and often triggers evolutionary arms races that lead to therapeutic resistance [2]. The "war" metaphor, while galvanizing, is a physically brutal, zero-sum strategy that often overlooks the complex, adaptive system of the patient's entire biology.

2. DEFINING THE NONPHYSICAL PRIMITIVE: CARE AS A REGULATORY AXIOM

We define Care, a nonphysical phenomenon, as: *the impetus that assigns terminal value to the state of another system* [3]. In biocentric AI alignment, this primitive transforms a recursive optimizer into a steward by giving it a reason to value the flourishing of the external world over selfish goals. It is not an emotion, but a foundational rule for decision-making.

3. TRANSLATING CARE TO ONCOLOGY: FROM CYTOTOXIC CAMPAIGN TO SYSTEMIC STEWARDSHIP

Applying this primitive to oncology reframes the objective from "kill all cancer cells" to "**minimize the total suffering of the host system.**" This shifts the therapeutic philosophy in critical ways:

3.1. The Prime Directive: Minimize Host Suffering

The primary utility function becomes the holistic well-being of the patient, a composite metric including tumor burden, immune function, organ integrity, neurological health, and psychological state. A therapy that decimates a tumor but permanently cripples the patient's quality of life is a sub-optimal outcome under this framework.

3.2. Therapeutic Protocols Guided by Care

- **The Precautionary Principle:** Favor diagnostic and therapeutic interventions with the lowest risk of irreversible harm to healthy system functions.
- **The Reversibility Principle:** Prioritize treatments whose effects on non-target systems can be repaired or compensated for.
- **The Therapeutic Suffering Principle:** Justify short-term, localized suffering (e.g., surgical trauma, localized inflammation) only when it demonstrably prevents greater, long-term systemic suffering.

3.3. Leveraging the Host's "Biological Intelligence"

A Care-driven approach actively seeks to recruit and strengthen the patient's innate regulatory systems. Instead of suppressing the immune system to avoid autoimmunity during treatment, the goal becomes to *steer* it—using emerging immunotherapies not as a blunt weapon, but as a precision tool to re-educate and re-integrate the immune response, fostering a sustainable, self-regulating state of health [4].

4. AN APPLIED EXAMPLE: CARE IN TREATMENT ALGORITHM DESIGN

Consider an AI-driven treatment planner operating on the principle of Care. Faced with an aggressive cancer, its goal is not simply to select the drug with the highest tumor kill rate. It would simulate and weigh:

- The drug's cytotoxicity to cancerous versus healthy stem cells.
- The long-term risk of triggering secondary malignancies.
- The impact on the patient's cognitive function and mental health.
- The potential for inducing immune memory versus tolerance.

The optimal solution is the one that achieves disease control while maximizing the patient's long-term functional flourishing—a direct application of minimizing systemic suffering.

5. DISCUSSION AND CONCLUSION

The "War on Cancer" is a physical battle fought with physical tools. While necessary, it is an incomplete strategy. The introduction of a nonphysical primitive, Care, provides a higher-order regulatory framework. It transforms the physician's role from a military commander to a **system steward**, and the therapeutic goal from eradication to the establishment of a **stable, healthy equilibrium**.

This framework does not render existing therapies obsolete; it provides a meta-protocol for their more intelligent, humane, and ultimately effective application. By adopting a stewardship model grounded in Care, oncology can advance from winning battles to sustainably winning the health of the patient. This demonstrates the universal applicability of nonphysical primitives in solving complex, adaptive challenges.

REFERENCES

- [1] Weinberg, R. A. "The Biology of Cancer." Garland Science, 2013.
- [2] Hanahan, D., & Weinberg, R. A. "Hallmarks of Cancer: The Next Generation." *Cell*, vol. 144, no. 5, 2011, pp. 646-674.
- [3] Philps, A. "The Ontology of Care: A Nonphysical Primitive in Conscious Systems." *International Journal of Healthcare Sciences*, vol. 13, no. 2, 2025, pp. 35-36.
- [4] Couzin-Frankel, J. "Breakthrough of the year: Cancer immunotherapy." *Science*, vol. 342, no. 6165, 2013, pp. 1432-1433.
- [5] Topol, E. J. "High-performance medicine: the convergence of human and artificial intelligence." *Nature Medicine*, vol. 25, 2019, pp. 44–56.